• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.

作者信息

Fanotto Valentina, Uccello Mario, Pecora Irene, Rimassa Lorenza, Leone Francesco, Rosati Gerardo, Santini Daniele, Giampieri Riccardo, Di Donato Samantha, Tomasello Gianluca, Silvestris Nicola, Pietrantonio Filippo, Battaglin Francesca, Avallone Antonio, Scartozzi Mario, Lutrino Eufemia Stefania, Melisi Davide, Antonuzzo Lorenzo, Pellegrino Antonio, Ferrari Laura, Bordonaro Roberto, Vivaldi Caterina, Gerratana Lorenzo, Bozzarelli Silvia, Filippi Roberto, Bilancia Domenico, Russano Marco, Aprile Giuseppe

出版信息

Oncologist. 2018 Feb;23(2):272. doi: 10.1634/theoncologist.2017-0158erratum.

DOI:10.1634/theoncologist.2017-0158erratum
PMID:29449512
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5813760/
Abstract
摘要

相似文献

1
Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.接受至少三线全身化疗的晚期胃癌患者的治疗结果。
Oncologist. 2018 Feb;23(2):272. doi: 10.1634/theoncologist.2017-0158erratum.
2
Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.至少接受三线全身化疗的晚期胃癌患者的治疗结果。
Oncologist. 2017 Dec;22(12):1463-1469. doi: 10.1634/theoncologist.2017-0158. Epub 2017 Aug 31.
3
[Three successful case reports of advanced gastric cancer with chemotherapy].[晚期胃癌化疗的三例成功病例报告]
Gan To Kagaku Ryoho. 2004 Oct;31(11):1689-92.
4
Benefits of intra-operative systemic chemotherapy during curative surgery in patients with locally advanced gastric cancer.术中全身化疗在局部进展期胃癌根治术中的应用价值。
Chin Med J (Engl). 2013;126(18):3493-8.
5
Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy.接受二线化疗的晚期胃癌患者的生活质量
Cancer Chemother Pharmacol. 2006 Feb;57(3):289-94. doi: 10.1007/s00280-005-0055-y. Epub 2005 Jul 12.
6
[Stage IV Gastric Cancer with Positive Peritoneal Washing Cytology or Peritoneal Dissemination Was Successfully Treated with Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy(HIPEC)Followed by Systemic Chemotherapy - A Report of Two Cases].[IV期胃癌伴腹水细胞学阳性或腹膜播散经胃切除术及腹腔内热灌注化疗（HIPEC）联合全身化疗成功治疗——两例报告]
Gan To Kagaku Ryoho. 2016 Nov;43(12):1954-1956.
7
Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer.肿瘤标志物癌胚抗原（CEA）、糖类抗原19-9（CA19-9）和糖类抗原125（CA125）在晚期胃癌患者全身化疗疗效监测中的应用
Jpn J Clin Oncol. 1999 Nov;29(11):550-5. doi: 10.1093/jjco/29.11.550.
8
[Three patients with advanced nonresectable and recurrent gastric cancer responding to chronomodulation chemotherapy with tegafur + cisplatin + isovorin followed by CPT-11 administration].
Gan To Kagaku Ryoho. 2002 Aug;29(8):1439-45.
9
CRS-HIPEC Prolongs Survival but is Not Curative for Patients with Peritoneal Carcinomatosis of Gastric Cancer.CRS-HIPEC可延长胃癌腹膜转移患者的生存期，但无法治愈该疾病。
Ann Surg Oncol. 2016 Nov;23(12):3972-3977. doi: 10.1245/s10434-016-5306-0. Epub 2016 Jun 16.
10
TP53 Codon 72 Polymorphism Predicts Efficacy of Paclitaxel Plus Capecitabine Chemotherapy in Advanced Gastric Cancer Patients.TP53基因第72位密码子多态性可预测晚期胃癌患者接受紫杉醇联合卡培他滨化疗的疗效。
Arch Med Res. 2016 Jan;47(1):13-8. doi: 10.1016/j.arcmed.2015.12.001. Epub 2015 Dec 13.

引用本文的文献

1
How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?雷莫西尤单抗如何有助于改善胃肠道癌症患者的治疗结果？
Cancers (Basel). 2021 Jul 15;13(14):3536. doi: 10.3390/cancers13143536.
2
Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN).超越指南：胃癌管理的灰色地带。来自意大利胃癌网络（GAIN）的共识声明。
Cancers (Basel). 2021 Mar 15;13(6):1304. doi: 10.3390/cancers13061304.
3
A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial.FGFR抑制剂培米替尼在转移性食管胃交界部/胃癌曲妥珠单抗耐药患者中的II期试验：FiGhTeR试验
Ther Adv Med Oncol. 2020 Jul 7;12:1758835920937889. doi: 10.1177/1758835920937889. eCollection 2020.
4
Stenting as a bridge to surgery for extra-colonic malignancy induced colorectal obstruction: preliminary experience.支架置入术作为结直肠恶性肿瘤性梗阻的外科手术桥接：初步经验。
BMC Gastroenterol. 2020 Apr 19;20(1):117. doi: 10.1186/s12876-020-01273-4.
5
Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma.贝伐珠单抗（FPA144）治疗晚期实体瘤和 FGFR2b 选择型胃食管腺癌的 I 期递增和扩展研究。
J Clin Oncol. 2020 Jul 20;38(21):2418-2426. doi: 10.1200/JCO.19.01834. Epub 2020 Mar 13.
6
Beyond the Beyond: A Case of an Extraordinary Response to Multiple Lines of Therapy in a de novo Metastatic HER2-Negative Gastric Cancer Patient.超越极限：一例初治转移性HER2阴性胃癌患者对多线治疗的非凡反应病例
Gastrointest Tumors. 2018 Sep;5(1-2):14-20. doi: 10.1159/000488983. Epub 2018 Jul 27.